Prelude Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Prelude Therapeutics Incorporated

10/03/2023 12:24

* Prelude Therapeutics Inc  PRLD.OQ   PRLD.O  is expected
to show
no change in quarterly revenue when it reports  results on March
14 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Prelude
Therapeutics Inc
is for a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $10​, above​ its last closing price
of $5.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.63       -0.64      -0.63     Beat    0.9
 Jun. 30 2022  -0.60       -0.61      -0.58     Beat    4.9
 Mar. 31 2022  -0.65       -0.65      -0.63     Beat    3.1​
 Dec. 31 2021  -0.67       -0.68      -0.71     Missed  -4
 ​​Sep.        -0.63       -0.62      -0.66     Missed  -5.6
 30 2021                                                
 Jun. 30 2021  -0.49       -0.49      -0.58     Missed  -17.4​
 Mar. 31 2021  -0.43       -0.42      -0.47     Missed  -10.8
 Dec. 31 2020  -0.47       -0.47      -0.45     Beat    3.7
 This summary was machine generated March 10 at 12:24 GMT.  All
figures in US dollars  unless otherwise stated